NASDAQ
15.05.25 | 16:28
0,131 US-Dollar
+17,75 % +0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 07.05. | Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 | 5 | GlobeNewswire (USA) | ||
| LYRA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.05. | Lyra Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 06.05. | Lyra Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 06.05. | Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update | 77 | GlobeNewswire (Europe) | WATERTOWN, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company developing long-acting, anti-inflammatory... ► Artikel lesen | |
| 13.03. | Lyra Therapeutics GAAP EPS of -$1.43 misses by $0.10, revenue of $1.53M | 1 | Seeking Alpha | ||
| 13.03. | Lyra Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.03. | Lyra Therapeutics, Inc. - 10-K, Annual Report | 3 | SEC Filings | ||
| 13.03. | Lyra Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.03. | Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | 417 | GlobeNewswire (Europe) | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients, expected in 2Q 2025In parallel, the Company continues to analyze data and explore opportunities... ► Artikel lesen | |
| 10.01. | Lyra Therapeutics, Inc. - 8-K, Current Report | 6 | SEC Filings | ||
| 13.12.24 | Lyra Therapeutics, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 12.11.24 | Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 200 | GlobeNewswire (Europe) | Company continues to focus on upcoming results from ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients expected in 2Q 2025 Company reports topline safety results from ENLIGHTEN 1 Phase 3 extension... ► Artikel lesen | |
| 15.10.24 | Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis | 172 | GlobeNewswire (Europe) | -- Topline Results Expected Q2 2025 -- WATERTOWN, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) ("Lyra" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| 14.08.24 | Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 214 | GlobeNewswire (Europe) | - Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned - - In parallel... ► Artikel lesen |
14 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 22,665 | +2,23 % | UBS stuft BAYER AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Bayer auf "Neutral" mit einem Kursziel von 22 Euro belassen. Bei der Quartalszahlenvorlage am 13. Mai dürfte der Fokus auf Fortschritten bei... ► Artikel lesen | |
| PFIZER | 19,972 | +1,44 % | Dividendenbekanntmachungen (09.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AAK AB SE0011337708 5 SEK 0,4573 EUR ADDLIFE AB SE0014401378 0,75 SEK 0,0686 EUR ALLIANZ SE DE0008404005 - 15,4 EUR ALZCHEM GROUP... ► Artikel lesen | |
| SANOFI | 89,41 | +0,65 % | Dividendenbekanntmachungen (12.05.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AKER BP ASA NO0010345853 6,5173 NOK 0,5586 EUR ALEXANDERS INC US0147521092 4,5 USD 4,0005 EUR AMG CRITICAL MATERIALS NV NL0000888691 0... ► Artikel lesen | |
| INNOCAN PHARMA | 0,109 | +2,35 % | Innocan Pharma Aktie: BRUTALE PROGNOSE zwingt Anleger zum Handeln. So sollten Sie HEUTE reagieren! | ||
| ARZNEIWERK AG VIDA | 0,620 | +6,90 % | PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Arzneiwerk AG VIDA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Arzneiwerk... ► Artikel lesen | |
| CRESCO LABS | 0,611 | -3,78 % | Cresco Labs slips after delaying Q1 earnings call | ||
| ASSEMBLY BIOSCIENCES | 10,900 | -0,91 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates | - Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in... ► Artikel lesen | |
| CSPC PHARMA | 0,639 | -3,03 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT WITH CIPLA USA, INC. FOR IRINOTECAN LIPOSOME INJECTION | ||
| TONIX PHARMACEUTICALS | 19,400 | -2,02 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights | FDA PDUFA goal date of August 15, 2025, for TNX-102 SL for the management of fibromyalgia; if approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years Announced... ► Artikel lesen | |
| AMARIN | 8,850 | -2,75 % | Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y | ||
| NEWRON PHARMACEUTICALS | 8,570 | -1,04 % | EQS-News: Newron Pharmaceuticals S.p.A.: Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwicklungsprogramm ENIGMA-TRS mit Evenamide als Zusatztherapie bei Patienten mit behandlungsresistenter Schizophrenie (TRS) bekannt | EQS-News: Newron Pharmaceuticals S.p.A.
/ Schlagwort(e): Studie
Newron gibt Genehmigung für zulassungsrelevantes Phase-III-Entwicklungsprogramm ENIGMA-TRS mit Evenamide als Zusatztherapie... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 0,621 | -2,51 % | Nektar Therapeutics Q1 Loss Increases, Misses Estimates | WASHINGTON (dpa-AFX) - Nektar Therapeutics (NKTR) released Loss for its first quarter that increased from last year and missed the Street estimates.The company's bottom line came in at -$50.88... ► Artikel lesen | |
| COMPASS PATHWAYS | 3,480 | +0,58 % | Compass Pathfinder Limited: Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights | Highlights: 6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late June Phase 3 COMP006 in TRD on track for 26-week data second... ► Artikel lesen | |
| JAGUAR HEALTH | 5,750 | -4,64 % | Jaguar Health, Inc.: Jaguar Health to Hold Investor Webcast Thursday, May 15 at 4:15 PM Eastern Regarding Q1 2025 Financials & Corporate Updates | Click here to registerCompany plans to file its Earnings Report on May 15, 2025 on Form 10-Q for the quarter ended March 31, 2025 SAN FRANCISCO, CA / ACCESS Newswire / May 14, 2025 / Jaguar Health,... ► Artikel lesen | |
| ROYALTY PHARMA | 28,930 | +0,07 % | Royalty Pharma plc: Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition | Received overwhelming shareholder approval with 99.9% of votes cast in favorSimplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant... ► Artikel lesen |
LYRA THERAPEUTICS INC gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,131 Euro und damit +17,75 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYRA THERAPEUTICS INC finden Sie auf Wallstreet Online.